# SMS Pharmaceuticals Limited (SMSPHARMA)

> SMSPHARMA closed at ₹511.35 on 30 Oct 2026, trailing P/E 46.6, market cap ₹4,789 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

SMS Pharmaceuticals Limited (NSE: SMSPHARMA) closed at ₹511.35 on 30 Oct 2026, +74.5% over one year, against a 52-week range of ₹270.10 – ₹525.00.

In the quarter ended 30 Jun 2026 (consolidated, filed 31 Jul 2026) it reported revenue of ₹207 cr and net profit of ₹21 cr, a 10.1% net margin; revenue grew 5.6% and profit grew 11.6% year on year.

On four consecutive filed quarters its trailing P/E is 46.6; since 30 May 2025 its own P/E has ranged from 26.3 to 45.5 (median 35.3), and today's reading is higher than 100% of those 350 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 10.6%, ROCE 13.0%, debt-to-equity 0.46, Piotroski F-score 6 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 25% of 64 sector peers; PBT margin higher than 27% of 64 sector peers; ROE higher than 28% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹511.35 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | +7.9% / +28.9% / +74.5% |
| 52-week low – high | ₹270.10 – ₹525.00 |
| Market capitalisation | ₹4,789 cr |
| Trailing P/E | 46.6 |
| Price / book | 6.09 |
| EV / EBITDA | 28.0 |
| Earnings yield | 2.1% |
| TTM EPS | ₹10.97 |
| TTM net profit | ₹103 cr |
| Quarter revenue | ₹207 cr |
| Quarter net profit | ₹21 cr |
| Net margin | 10.1% |
| Revenue growth (YoY) | +5.6% |
| Profit growth (YoY) | +11.6% |
| Return on equity | 10.6% |
| ROCE | 13.0% |
| Debt / equity | 0.46 |
| Current ratio | 1.81 |
| Free cash flow | ₹-71 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹15.1 cr |

## Questions

### What is the P/E ratio of SMS Pharmaceuticals Limited?

SMS Pharmaceuticals Limited's trailing P/E is 46.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 30 May 2025 its P/E has ranged 26.3–45.5.

### What were SMS Pharmaceuticals Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, SMS Pharmaceuticals Limited reported revenue of ₹207 cr and net profit of ₹21 cr (consolidated), filed with the exchange on 31 Jul 2026.

### What is SMS Pharmaceuticals Limited's ROE?

Return on equity is 10.6% based on the balance sheet dated 31 Mar 2026.

### Does SMS Pharmaceuticals Limited have debt?

Debt-to-equity is 0.46 on the balance sheet dated 31 Mar 2026.

### What is SMSPHARMA's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, SMSPHARMA traded between ₹270.10 and ₹525.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/SMSPHARMA

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._